Physician profile
Mary E Scott
NPI 1124177514
$7,215.36
in general payments reported to CMS, 2019-2025
30 companies · $894 in 2025
The $894 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,953 · 2022: $397 · 2023: $2,144 · 2024: $828 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735 · Travel and Lodging: $1,085 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,735.33 |
| Travel and Lodging | $1,084.97 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,497.59 | 2021-2025 | Briviact, Nayzilam |
| Boston Scientific Corporation | $1,424.29 | 2021 | |
| Medtronic, INC. | $1,187.63 | 2021-2024 | Percept PC Brainsense |
| Abbvie INC. | $580.02 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $428.12 | 2021-2025 | Austedo Xr, Austedo Xr |
| Acadia Pharmaceuticals INC | $367.29 | 2021-2025 | Nuplazid, Daybue |
| Novartis Pharmaceuticals Corporation | $285.90 | 2023-2025 | |
| Kyowa Kirin, INC. | $243.87 | 2021-2024 | Nourianz |
| Neurocrine Biosciences, INC. | $204.71 | 2021 | |
| Amneal Pharmaceuticals LLC | $183.23 | 2021-2025 | Crexont, Ongentys 50mg Capsules 30, Rytary |
| Sk Life Science, INC. | $158.66 | 2021-2025 | |
| Inspire Medical Systems, INC. | $92.85 | 2023 | Inspire |
| Neurelis, INC. | $86.39 | 2024-2025 | Valtoco |
| Aquestive Therapeutics, INC. | $57.82 | 2021-2022 | |
| Tg Therapeutics, INC. | $50.13 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $41.00 | 2023-2025 | Hizentra |
| Eisai INC. | $36.73 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $33.47 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $31.97 | 2025 | Xeomin |
| Lilly USA, LLC | $27.72 | 2023-2024 | Reyvow, Emgality, Amyvid |
| Amgen INC. | $25.46 | 2021-2022 | |
| Genentech USA, INC. | $25.12 | 2025 | Ocrevus Zunovo |
| Biohaven Pharmaceuticals, INC. | $24.95 | 2021 | |
| Jazz Pharmaceuticals INC. | $24.40 | 2024 | |
| Biocodex, INC. | $22.51 | 2024 | |
| Abbott Laboratories | $18.27 | 2024 | Infinity |
| Alexion Pharmaceuticals, INC. | $15.76 | 2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $13.86 | 2025 | Wainua |
| Genzyme Corporation | $13.46 | 2025 | |
| Biogen, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.